For future work, we aim to expand the framework to incorporate additional data modalities such as different MRI contrasts (FLAIR, FSE, diffusion weighted imaging), amyloid- and tau-PET tracers, and resting-state fMRI and mild-cognitive-impairment (MCI) data; to measure how stable the saliency maps remain under adversarial perturbations and domain shifts; and to test the approach on other neuro-degenerative diseases or complex medical conditions, thereby enhancing its versatility and potential impact on medical diagnostics. Here, MAPT is linked to Neurodegeneration.